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Abstract
Different genes are associated with categorical classifications of asthma severity. However,
continuous outcomes should be used to catch the heterogeneity of asthma phenotypes and
to increase the power in association studies. Accordingly, the aim of this study was to evalu-
ate the association between single nucleotide polymorphisms (SNPs) in candidate gene
regions and continuous measures of asthma severity, in adult patients from the general
population. In the Gene Environment Interactions in Respiratory Diseases (GEIRD) study
(www.geird.org), 326 subjects (aged 20–64) with ever asthma were identified from the gen-
eral population in Verona (Italy) between 2007 and 2010. A panel of 236 SNPs tagging 51
candidate gene regions (including one or more genes) was analysed. A symptom and treat-
ment score (STS) and pre-bronchodilator FEV1% predicted were used as continuous mea-
sures of asthma severity. The association of each SNP with STS and FEV1% predicted was
tested by fitting quasi-gamma and linear regression models, respectively, with gender, body
mass index and smoking habits as potential confounders. The Simes multiple-test proce-
dure was used for controlling the false discovery rate (FDR). SNP rs848 in the IL13 gene
region (IL5/RAD50/IL13/IL4) was associated with STS (TG/GG vs TT genotype: uncor-
rected p-value = 0.00006, FDR-corrected p-value = 0.04), whereas rs20541 in the same
gene region, in linkage disequilibrium with rs848 (r2 = 0.94) in our sample, did not reach the
statistical significance after adjusting for multiple testing (TC/CC vs TT: uncorrected p-value
= 0.0003, FDR-corrected p-value = 0.09). Polymorphisms in other gene regions showed a
non-significant moderate association with STS (IL12B, TNS1) or lung function (SERPINE2,
GATA3, IL5, NPNT, FAM13A) only. After adjusting for multiple testing and potential con-
founders, SNP rs848 in the IL13 gene region is significantly associated with a continuous
measure of symptom severity in adult subjects with ever asthma.
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Introduction
Asthma is a complex chronic disease that involves the interaction among multiple genetic,
environmental and life-style factors. The genetic of asthma has been investigated in many asso-
ciation studies, which have shown that different genes are likely to play a role in disease sever-
ity. In fact, polymorphisms in ADRB2 [1], ARG1 and ARG2 [2], CTLA4 [3], IL4 [4], IL4R [5],
IL18 [6], TGFB1 [7] and TLR4 [8] genes are associated with asthma severity in several popula-
tions. In addition, polymorphisms in ADAM33 are associated with adult-onset asthma and dis-
ease severity [9], and this gene and ADAM8 may contribute to the remodelling process that
occurs with asthma progression [10]. Moreover, IL6R variation Asp358Ala is a potential modi-
fier of lung function in asthma, and it may identify subjects at risk for a more severe form of
their disease [11]. In children and young adults, CHI3L1 is associated with asthma-related hos-
pital admissions [12], whereas a polymorphism controlling the expression of ORMDL3 is asso-
ciated with poor control of the disease in the same age class [13]. In addition, SERPINE1 is
related to asthma severity and the response to inhaled corticosteroids [14]. Finally, the expres-
sion of IL33 increases in patients with a severe form of the disease [15].
In the 2002 Global INitiative for Asthma (GINA) guidelines [16], the definition of asthma
severity was based on a composite categorical classification of lung function, symptom fre-
quency and the daily medication regimen. However, in epidemiological studies, continuous
outcomes should be used to catch the heterogeneity of asthma phenotypes that may result
from different risk factors. The utilization of continuous measures of disease severity is also jus-
tified by the fact that any categorical classification is biologically unsatisfactory for chronic ill-
nesses [17]. In addition, continuous outcomes could increase the power in association studies.
Finally, genetic association analyses should be carried out on each dimension of asthma sever-
ity (i.e. lung function, symptom frequency and treatment intensity), because different genes
can play a role in these different dimensions. In fact, in the French Epidemiological study on
the Genetics and Environment of Asthma, new genomic regions were associated with a score
of symptom frequency and treatment intensity, but this score had no genetic determinants in
common with lung function [18].
The present study is aimed at assessing the association between candidate gene polymorphisms
and continuous measures of disease severity in adult subjects with ever asthma, who were identified
from the general population in Italy. The analysis was carried out by using the data from the Gene
Environment Interactions in Respiratory Diseases (GEIRD) study (www.geird.org) [19].
Materials and Methods
Design of the GEIRD study
GEIRD is an ongoing, multicentre, (multi)case-control study on respiratory health [19], in
which cases and controls are identified through a two-stage screening process (postal question-
naire and clinical examination) in pre-existing cohorts or in new random samples from the
general population in Italy. A screening questionnaire (stage 1; 2007/2010) was mailed to 7,413
subjects aged 20–64 (response rate: 70.7%) in the Verona centre. All the responders with symp-
toms suggestive of asthma, chronic obstructive pulmonary disease (COPD) or chronic bron-
chitis (n = 1,003), and a random sample of the responders with no respiratory symptoms or
with symptoms suggestive of rhinitis (n = 1,614), were invited to undergo a detailed clinical
interview and lung function tests for accurate phenotyping, and to provide blood samples for
genotyping (stage 2; 2008/2010) (Fig 1). By December 2013, 1,174 of these subjects were exam-
ined in the Verona clinic and 1,000 were genotyped. In order to fulfil the purpose of the present
study, only the cases of asthma were included in the analysis.
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Ethics approval was obtained from the appropriate ethics committee (“Comitato Etico per la
Sperimentazione dell'Azienda Ospedaliera Istituti Ospitalieri di Verona”). All participants were fully
informed about all the aspects of the research project and they gave written informed consent.
Cases of asthma
In Verona, 375 cases of asthma were identified at the clinical examination. Of these patients,
326 provided genetic data and complete information on the severity of their disease (Fig 1).
A subject was defined as having asthma if he/she fulfilled at least one of the following criteria:
1. having reported ever asthma;
2. having reported asthma-like symptoms [wheezing, nocturnal tightness in the chest, short-
ness of breath (SoB) following strenuous activities, SoB at rest, SoB at night time] or anti-
asthmatic treatment in the past 12 months, and having at least one of the following
conditions:
a. airflow hyperresponsiveness (AHR; PD201 mg);
b. pre-bronchodilator airflow obstruction (AO; FEV1/FVC<70% or<Lower Limit of Nor-
mal, according to Quanjer [20]) and a positive reversibility test (increase in FEV1>12%
and>200 ml with respect to pre-bronchodilator FEV1 after 400 mcg of salbutamol);
c. pre- but not post-bronchodilator AO, and post-bronchodilator FEV180% predicted [20].
Measures of asthma severity
Two measures of asthma severity were analysed: pre-bronchodilator FEV1% predicted, which
is as an objective marker of disease severity, and a continuous score of the presence/frequency
Fig 1. Flow chart of the GEIRD study in the Verona centre and selection of the 326 cases of asthma
included in the analysis.
doi:10.1371/journal.pone.0151292.g001
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of respiratory symptoms and of the intensity of anti-asthmatic treatment reported at the clini-
cal interview (symptom and treatment score, STS).
STS was obtained as a weighted linear combination of the following variables: (i) frequency
of asthma attacks (none, 1–2, 3–11,12) in the past 12 months; (ii) frequency of wheezing
(never, sometimes, at least once a week) in the past 12 months; (iii) presence of nocturnal tight-
ness in the chest in the past 12 months; (iv) presence of SoB following strenuous activities in
the past 12 months; (v) presence of SoB at rest in the past 12 months; (vi) presence of SoB at
night time in the past 12 months; (vii) chronic bronchitis (i.e. cough or phlegm from the chest,
usually in winter and on most days for a minimum of three months a year and for at least two
successive years); (viii) presence of episodes when symptoms were a lot worse than usual or
having reported at least one emergency department visit/hospital admission for respiratory
problems in the past 12 months; (ix) intensity of anti-asthmatic treatment [no treatment for
asthma, GINA step 1 (only relievers), GINA step 1 (controllers), GINA steps2] in the past 12
months. STS was computed through a multiple factor analysis with the symptoms grouped
into a single set of variables [21]. It ranges from 0 (no symptoms/treatment for asthma) to 10
(maximum frequency of symptoms and GINA steps2) and its distribution is approximately
an over-dispersed gamma (Fig 2). The concurrent and predictive validity, and the external rep-
lication of STS were verified by using the data from the GEIRD study and the European Com-
munity Respiratory Health Survey II [22] (data not shown).
Genetic protocol
In the GEIRD study, a panel of 384 single nucleotide polymorphisms (SNPs), which tag 53 can-
didate gene regions (including one or more genes), was analysed (S1 Table). The gene regions
were chosen on the basis of a previous indication of association with asthma, COPD or rhinitis
[from candidate gene or genome-wide association studies (GWAS)], or because of their
involvement in biological pathways that are probably related to these respiratory diseases. The
selected polymorphisms included both SNPs tagging most of haplotype variability in the CEU
population (HapMAp phase II) and candidate SNPs from literature. Genotyping was carried
out by means of a customized GoldenGate Genotyping assay.
Fig 2. Distribution of the symptom and severity score among the 326 cases of asthma included in the
analysis.
doi:10.1371/journal.pone.0151292.g002
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Two hundred and thirty six SNPs (representative of 51 candidate gene regions) fulfilled the
quality control and they had5% of missing values and the minimum genotype frequency
5% in our sample. These SNPs were included in the present analysis and were tested accord-
ing to the additive, dominant and recessive genetic models. The homozygous genotype with
the lower allele frequency was considered as the reference.
Statistical analysis
The association of each SNP with STS and FEV1% predicted was evaluated by using quasi-
gamma (with log link) [23] and linear regression models, respectively. In order to take the
extra variability into account, the quasi-gamma models were fitted through the iterated,
reweighted least-squares optimization of the deviance, with the scale parameter set to the Pear-
son chi-squared statistic divided by the residual degrees of freedom. All the regression models
had the genotype (classified according to the additive, dominant or recessive genetic model),
gender, body mass index (BMI) and smoking habits as covariates. The strength of the associa-
tion between each SNP and STS was measured through the ratio of expected scores (RES),
whereas the strength of the association with FEV1% predicted was measured through the beta
regression coefficient, which represents the difference between two genotypes in the expected
FEV1% predicted. For each outcome, the 708 p-values (obtained after having tested the 236
SNPs according to the three genetic models) were corrected for controlling the false discovery
rate (FDR) by using the Simes multiple-test procedure [24].
The statistical analysis was performed by using STATA software, release 13 (StataCorp, Col-
lege Station, TX), and R software, version 3 (The R Foundation for Statistical Computing,
Vienna, Austria).
Results
Main characteristics of the asthmatic subjects
The 326 cases of asthma included in the present analysis were on average 42.7 years old
(Table 1). Of these individuals, 50.3% were females, 52.8% were ever smokers, and 62.6% had a
symptomatic disease (i.e. they had reported the use of anti-asthmatic treatment or at least one
asthma attack or at least one asthma-like symptom or the presence of episodes when symptoms
were a lot worse than usual or the use of hospital services due to breathing problems in the past
12 months, or coexisting chronic bronchitis). In particular, one out of four patients had used
controller medications for asthma in the past 12 months. In addition, 42.6% of the studied indi-
viduals had reported an early-onset asthma (<10 years)
The distribution of the demographic and clinical variables, smoking habits and pharmaco-
logical treatment for asthma was not significantly different between the studied patients and
the 49 cases of asthma that had not been included in the present analysis (due to the absence of
their genetic data and/or incomplete information on the severity of their disease) (Table 1).
SNPs associated with symptom severity
Only one SNP (rs848) in the IL13 gene region (IL5/RAD50/IL13/IL4) was significantly associ-
ated with symptom frequency and treatment intensity (TG/GG vs TT genotype: uncorrected p-
value = 0.00006, FDR-corrected p-value = 0.04) (Fig 3). In fact, the subjects with TG or GG
genotypes in rs848 had a three-fold increased expected STS as compared to the individuals
with TT genotype, the expected score being equal to 1.84 and 0.60 in the two groups of patients,
respectively (Table 2, Fig 4). In particular, the TG/GG patients showed a higher risk of
SNPs and Asthma Severity in Adults
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reporting wheezing, the use of controller medications for asthma, SoB following strenuous
activities and asthma attacks in the past 12 months, as compared to the TT individuals
(Table 3).
Table 1. Main characteristics of the asthmatic subjects identified in the GEIRD study, according to their inclusion in the analysis.
Cases of asthma
Included (n = 326) Not included* (n = 49) p-value†
Females, % 50.3 53.1 0.72
Age (years), mean ± sd 42.7 ± 9.7 43.9 ± 9.1 0.44
Smoking habits, % Never smoker 47.2 46.9 0.48
Past smoker 27.0 20.4
Current smoker 25.8 32.7
BMI, median (interquartile range) 24.3 (22.0–26.9) 24.7 (21.6–26.7) 0.61
At least one attack of asthma‡, % 17.8 14.6 0.58
Wheezing‡, % Never 64.1 59.6 0.36
Sometimes 30.4 29.8
At least once a week 5.5 10.6
Nocturnal tightness in the chest‡, % 17.5 27.7 0.09
Shortness of breath at rest‡, % 8.6 14.9 0.18
Shortness of breath following strenuous activities‡, % 19.9 21.3 0.83
Shortness of breath at night time‡, % 13.2 19.1 0.27
Chronic bronchitis, % 13.5 14.9 0.79
Worsening of symptoms or use of hospital services¶ ‡, % 14.4 7.0 0.18
Use of controller medications‡, % 24.2 17.9 0.38
FEV1% predicted, mean ± sd 102.7 ± 14.5 105.8 ± 14.0 0.42
* Due to the absence of their genetic data or incomplete information on the severity of their disease.
† P-values obtained by using two-sample t test, two-sample test on the equality of medians, χ2 test or Fisher exact test.
‡ In the past 12 months.
¶ Presence of episodes when symptoms were a lot worse than usual or having reported at least one emergency department visit/hospital admission for
respiratory problems.
doi:10.1371/journal.pone.0151292.t001
Fig 3. Associations of 236 SNPs in 51 candidate gene regions with the symptom and treatment score (a) and pre-bronchodilator FEV1% predicted (b),
according to the additive, dominant and recessive genetic models. Data represent the measure of association and the uncorrected p-value for the association
of each SNP with the outcome. The FDR-corrected cut-off (0.00007) for statistical significance is reported.
doi:10.1371/journal.pone.0151292.g003
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A second SNP (rs20541) in the IL13 gene region, which was in linkage disequilibrium (LD)
with rs848 (r2 = 0.94) in our sample, was similarly associated with STS, even if this association
did not reach the statistical significance after adjusting for multiple testing (TC/CC vs TT geno-
type: uncorrected p-value = 0.0003, FDR-corrected p-value = 0.09) (Table 2). Moreover, a non-
significant moderate association with STS was observed for rs2853694 in IL12B (AA vs CC/
AC) and for rs929936 in TNS1 (TC/CC vs TT).
SNPs associated with lung function
No SNPs were significantly associated with pre-bronchodilator FEV1% predicted after adjust-
ing for multiple testing (Fig 3). However, a non-significant moderate association with lung
function was observed for the following polymorphisms: rs6721140 in SERPINE2 (AG/AA vs
GG genotype), rs3802604 in GATA3 (TT vs CC/TC), rs2069812 in IL5 (according to the addi-
tive genetic model), rs6811135 in NPNT (INTS12/GSTCD/NPNT; according to the additive
genetic model) and rs2276936 in FAM13A (GG vs TT/TG) gene regions (Table 4). Moreover,
rs3802604 (GATA3) and rs2276936 (FAM13A) also showed a non-significant moderate asso-
ciation with lung function according to the additive genetic model, but there was no difference
between the reference and heterozygous genotypes in the expected FEV1% predicted. These
SNPs were not associated with symptom severity.
Discussion
The main results of the present analysis are the following:
• SNP rs848 in the IL13 gene region is significantly associated with a continuous measure of
symptom severity in adult subjects with ever asthma, who were identified from the general
population in Italy;
Table 2. Associations with symptom severity.
Gene
region
SNP* Genotype† Genetic
model
Number of
subjects
Expected STS‡
[95%CI]
Ratio of expected
scores‡ [95%CI]
Uncorrected p-
value
FDR-corrected
p-value
IL13 rs848 TT dominant 24 0.60 [0.28 to
0.91]
1.00 - -
TG/GG 299 1.84 [1.57 to
2.12]
3.09 [1.78 to 5.34] 0.00006 0.04
IL13 rs20541 TT dominant 21 0.63 [0.28 to
0.99]
1.00 - -
TC/CC 304 1.86 [1.58 to
2.13]
2.93 [1.64 to 5.23] 0.0003 0.09
IL12B rs2853694 CC/AC recessive 224 1.99 [1.66 to
2.31]
1.00 - -
AA 101 1.31 [0.99 to
1.63]
0.66 [0.49 to 0.89] 0.006 0.99
TNS1 rs929936 TT dominant 30 0.97 [0.53 to
1.42]
1.00 - -
TC/CC 295 1.84 [1.57 to
2.11]
1.89 [1.17 to 3.06] 0.009 0.99
SNP: single nucleotide polymorphism; STS: symptom and treatment score; 95%CI: 95% conﬁdence interval; FDR: false discovery rate.
* Only the SNPs with the uncorrected p-value <0.01 are reported.
† The homozygous genotype with the lower allele frequency is the reference.
‡ Adjusted for the effect of gender, BMI and smoking habits.
doi:10.1371/journal.pone.0151292.t002
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• after adjusting for multiple testing, polymorphisms in other gene regions show a non-signifi-
cant moderate association with symptom severity or lung function only.
SNPs in the IL13 gene region
Asthma symptoms are related to the presence of activated Th2 cytokine-producing cells (IL4,
IL5, IL9 and IL13) in the airway wall [25]. Although each of these cytokines probably contrib-
utes to the overall immune response to environmental antigens, IL13 may have a singular role
in the regulation of the allergic diathesis [25] and it is a critical mediator of allergic inflamma-
tion [26]. In fact, IL13 contributes to many key features of asthma [e.g. mucus production,
Immunoglobulin E (IgE) synthesis, bronchial fibrosis and AHR] and consequently it is an
attractive target for pharmacological intervention [26,27]. Therefore, a recent Phase II clinical
trial has shown that the IL13 blockade with lebrikizumab may improve disease control, even if
blocking IL13 is not sufficient to improve lung function [27]. Accordingly, a GWAS has
reported that IL13 is not associated with lung function [28].
These findings are supported by the fact that we identified one polymorphism (rs848) in the
IL13 gene region, which is significantly associated with a continuous measure of symptom
severity but it does not correlate with lung function. In addition, a second SNP (rs20541) in the
same gene region, which is in LD with rs848 in our sample, shows a less significant association
with the symptom score. This could be due to the relatively small sample size and the strong,
but not perfect, LD. However, these two SNPs (or other SNPs in the same LD block) are likely
to tag the same gene.
The relationship between rs848/rs20541 and asthma phenotypes has been found in different
age classes. In children, the two IL13 polymorphisms are associated with an increased risk of
Fig 4. Distribution of the symptom and treatment score among the cases of asthma, according to their
genotype in SNP rs848 in the IL13 gene region. The genotype is coded according to the dominant genetic
model (the homozygous genotype with the lower allele frequency is the reference). Diamonds represent the
expected scores, adjusted for gender, BMI and smoking habits.
doi:10.1371/journal.pone.0151292.g004
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wheezing and both SNPs interact with household carpet use on late-onset asthma [29]. In addi-
tion, rs20541 modifies the effect of maternal smoking during pregnancy and household envi-
ronmental tobacco smoke (ETS) on early-onset persistent wheezing in childhood [30]. The two
polymorphisms are also associated with the eosinophil count and serum total IgE in Costa
Rican and white (non-Hispanic) children with asthma [31], and rs20541 is related to elevated
IgE levels in three Dutch cohorts aged 1–8 [32]. Furthermore, both SNPs are associated with
cord blood IgE in Taiwanese full-term new-borns, particularly in males exposed to prenatal
ETS [33]. In adults, the role of rs20541 in asthma development has been reported in different
studies [34–37]. Moreover, this SNP is associated with AHR in an adult asthmatic Japanese
population [38], and it could increase eosinophilic inflammation in the upper and lower air-
ways of patients with aspirin-intolerant asthma [39], which is a severe form of the disease.
To the best of our knowledge, the association between rs20541 and lung function in asthma
has been reported with contrasting results [35,38,40–42], whereas no relationship between
rs848 and respiratory parameters has been found in African American adults with asthma [40].
SNPs in other gene regions
We found that rs2853694 in IL12B and rs929936 in TNS1 gene regions show a non-significant
moderate association with symptom severity. IL12B may be an important asthma gene [43]
and an IL12B promoter polymorphism is associated with the severity of atopic and non-atopic
Table 3. Main characteristics of the asthmatic subjects, according to their genotype* in SNP rs848 in the IL13 gene region.
rs848
TT (n = 24) TG/GG (n = 299) p-value†
Females, % 62.5 49.2 0.21
Age (years), mean ± sd 40.8 ± 9.8 42.9 ± 9.7 0.32
Smoking habits, % Never smoker 41.7 47.8 0.69
Past smoker 25.0 26.8
Current smoker 33.3 25.4
BMI, median (interquartile range) 24.2 (21.7–25.9) 24.4 (22.0–27.0) 0.56
At least one attack of asthma‡, % 4.2 18.7 0.09
Wheezing‡, % Never 91.6 62.2 0.005
Sometimes 4.2 32.1
At least once a week 4.2 5.7
Nocturnal tightness in the chest‡, % 12.5 17.7 0.78
Shortness of breath at rest‡, % 4.2 9.0 0.71
Shortness of breath following strenuous activities‡, % 4.2 21.1 0.06
Shortness of breath at night time‡, % 12.5 13.0 1.00
Chronic bronchitis, % 12.5 13.7 1.00
Worsening of symptoms or use of hospital services¶ ‡, % 16.7 14.4 0.76
Use of controller medications‡, % 4.2 25.4 0.02
FEV1% predicted, mean ± sd 101.6 ± 16.0 102.7 ± 14.3 0.70
* Coded according to the dominant genetic model; the homozygous genotype with the lower allele frequency is the reference. Three subjects had no
information on SNP rs848.
† P-values obtained by using two-sample t test, two-sample test on the equality of medians, χ2 test or Fisher exact test.
‡ In the past 12 months.
¶ Presence of episodes when symptoms were a lot worse than usual or having reported at least one emergency department visit/hospital admission for
respiratory problems.
doi:10.1371/journal.pone.0151292.t003
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asthma in children [44]. Moreover, a recent GWAS has identified a SNP in TNS1 with sugges-
tive evidence of its association with asthma and coexisting hay fever [45].
In the present analysis, polymorphisms in different gene regions (SERPINE2, GATA3, IL5,
NPNT, FAM13A) show a non-significant moderate association with lung function. SERPINE2
is associated with lung function in COPD patients [46], and it has been hypothesized that it is a
common genetic determinant of asthma and COPD (i.e. the Dutch hypothesis) [47]. However,
our results are in agreement with those from an association study between different SERPINE2
SNPs and asthma-related phenotypes, including lung function, which weakly support this
hypothesis [48]. To the best of our knowledge, an association between GATA3, which is an
important regulator of T-cell development, and lung function in asthma has been reported in
one abstract only [49]. IL5, which is an important cytokine for eosinophil-induced airway
inflammation and AHR, is associated with spirometric markers of disease severity in Korean
children with atopic asthma [50], whereas the relationship between a locus in INTS12/
GSTCD/NPNT and FEV1 has been identified in a meta-analysis of GWAS [51]. Finally,
FAM13A (a gene associated with COPD [52]) has been shown to predict lung function abnor-
malities in non-Hispanic white and African American subjects with asthma, together with
other lung function genes [53].
Table 4. Associations with lung function.
Gene
region
SNP* Genotype† Genetic
model
Number of
subjects
Expected FEV1%
predicted‡ [95%CI]
Beta regression
coefﬁcient‡ [95%CI]
Uncorrected p-
value
FDR-
corrected p-
value
SERPINE2 rs6721140 GG dominant 41 109.0 [104.7 to
113.3]
0.0 - -
AG/AA 284 102.0 [100.3 to
103.6]
-7.0 [-11.7 to -2.4] 0.003 0.86
GATA3 rs3802604 CC/TC recessive 185 100.7 [98.7 to 102.8] 0.0 - -
TT 139 105.5 [103.1 to
107.9]
4.7 [1.6 to 7.9] 0.004 0.86
IL5 rs2069812 TT additive 37 97.1 [92.5 to 101.8]¶ 0.0 - -
TC 138 101.9 [99.5 to
104.2]¶
3.5 [1.1 to 5.8]¥ 0.004 0.86
CC 150 104.7 [102.4 to
107.0]¶
7.0 (additive effect) - -
NPNT rs6811135 AA additive 67 106.7 [103.3 to
110.2]¶
0.0 - -
AG 169 102.5 [100.4 to
104.7]¶
-3.2 [-5.4 to -0.9]¥ 0.005 0.86
GG 90 100.2 [97.2 to
103.1]¶
-6.4 (additive effect) - -
FAM13A rs2276936 TT/TG recessive 241 101.4 [99.6 to 103.3] 0.0 - -
GG 85 106.4 [103.4 to
109.5]
5.0 [1.4 to 8.5] 0.006 0.86
SNP: single nucleotide polymorphism; 95%CI: 95% conﬁdence interval; FDR: false discovery rate.
* Only the SNPs with the uncorrected p-value <0.01 are reported.
† The homozygous genotype with the lower allele frequency is the reference.
‡ Adjusted for the effect of gender, BMI and smoking habits.
¶ Estimated after including the genotype as a qualitative variable in the regression model.
¥ Estimated after including the genotype as a quantitative variable in the regression model. The beta regression coefﬁcient represents the change in the
expected FEV1% predicted for 1-unit increase in the genotype variable according to the additive genetic model.
doi:10.1371/journal.pone.0151292.t004
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Strengths and weaknesses of our study
The main strength of the present analysis is that our subjects underwent an accurate phenotyp-
ing by means of an extended clinical interview and lung function tests [19]. Moreover, the data
were collected in patients who had been identified from the general population, rather than
from clinically selected groups, which should guarantee that our sample encompasses a wide
spectrum of disease severity. In addition, two continuous measures of disease severity were
used (STS and pre-bronchodilator FEV1% predicted). This choice is justified by the fact that
asthma severity is heterogeneous, and respiratory symptoms and lung function may have spe-
cific determinants. Accordingly, the use of continuous outcomes, rather than simple categorical
definitions, can improve the identification of risk factors by reducing misclassification of the
disease status [18]. Finally, a parametric modelling approach was adopted for STS, since it was
possible to assume a known theoretical distribution of the score (over-dispersed gamma), with
a consequent increase in the power of the association analysis. In fact, if non-parametric tests
were used because of the skewness in the score distribution, the association of rs848 with STS
would not have reached the statistical significance after the correction for multiple testing (data
not shown). Furthermore, parametric models are a powerful tool for controlling the effect of
potential confounders, such as gender, BMI and smoking habits.
A few caveats should be taken into account when interpreting our results. At the time of the
analysis, the genetic data were collected in a single centre only (Verona), which could limit the
generalizability of the results. In addition, both the sample size and the number of SNPs
included in the analysis are relatively small. However, the use of continuous measures of
asthma severity and the use of appropriate statistical methods made it possible to reduce the
weakness of our analysis with regard to the limited sample size.
Conclusions
After adjusting for multiple testing and potential confounders, SNP rs848 in the IL13 gene
region is significantly associated with a continuous measure of symptom severity in adult sub-
jects with ever asthma, who were identified from the general population in Italy. Polymor-
phisms in other gene regions show a non-significant moderate association with symptom
severity or lung function only.
Supporting Information
S1 Table. List of the 384 tag-SNPs in 53 candidate gene regions that were analysed in the
GEIRD study. The 236 tag-SNPs included in the association study are reported.
(PDF)
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